What I Wish I Knew Before Starting a GLP-1 (Wegovy/Ozempic) in 2026

The pen sat on the kitchen table for three days before I touched it.

I'd done the thing everyone does — read the success stories, read the horror stories, watched a stranger demonstrate the click on a phone screen at midnight. By the time the box arrived, I knew the marketing and the panic, and almost nothing in between. Nobody had told me what the actual year would feel like from the inside of it.

So this is the version I wish someone had handed me before I uncapped anything: what the trials measure, what the brochures skip, and the handful of things that would have saved me months of second-guessing. Every number here comes from the published research, not my own bathroom scale. Your story is yours to write with your doctor. This is just me, talking to the person who couldn't sleep the night before.

The pen on the table, and the four questions behind it

I wasn't chasing a magic fix. I wanted someone to talk to me like an adult.

Specifically, I had four questions, and I wanted plain answers to all of them. Does this thing really work? How rough is the start? How long am I signing up for? And what should I have checked before the first dose? That's the whole list. Everything else was noise.

The drug in my hand was semaglutide — sold as Wegovy for weight management and as Ozempic for type 2 diabetes, both from the same manufacturer. Same molecule, different dose, different label on the box. The FDA approved the obesity version in June 2021, and that one date did more to calm me down than any testimonial, because it meant there was real trial data underneath the hype instead of ring lights and affiliate codes.

So let me take the four questions in order.

Does it work? Yes — but the headline is an average, not a promise

The number everyone quotes comes from a trial called STEP 1.

Over 68 weeks, adults on semaglutide 2.4 mg lost an average of 14.9% of their body weight, against 2.4% on placebo. Strip out the placebo effect and the part you can credit to the drug itself is about 12.4 percentage points. In plain kilos, that came to roughly 15.3 kg lost on the drug versus 2.6 kg on placebo.

That is a striking result for a medication, and I won't pretend otherwise — the size of the effect was bigger than anything I'd read about before.

But sit with the word average for a second. It's quietly doing a lot of work.

An average is one number standing in for a thousand different bodies. Some people blew past it. Some barely budged. The headline tells you where the middle of the crowd landed — not where you'll land.

I treated "14.9%" like a forecast I could bank on. What I didn't get yet was that a forecast is a range wearing the costume of a single point.

Your number probably won't be the headline number

This is the part I most wish I'd absorbed before week one, because it's where a lot of people quietly lose faith for no good reason.

STEP 1 didn't just report an average. It reported how many people crossed specific lines — and that spread, not the headline, is the real story:

Run your eye down the middle column. About 86% lost at least 5%. Roughly 69% lost at least 10%. And right around half — 50.5% — lost 15% or more.

Half. Half the people on the drug cleared the big number, and the other half didn't, all of them taking the identical medicine at the identical dose. That gap isn't effort or willpower. It's biology you didn't pick.

Once that table sank in, the pressure lifted. I'd been treating 15% as a debt I somehow owed the universe. It isn't a target you hit or miss — it's the upper-middle of a wide distribution, and where you fall in it is mostly out of your hands. If your loss runs slower or smaller, you aren't failing the drug and the drug isn't failing you. You're a data point, same as everyone else in that trial.

The kindest thing I eventually did for myself was stop weighing every morning and start reading the trend by the month.

Yes, the nausea is real — and it's front-loaded

Nobody warned me the rough part shows up early and then mostly leaves.

In STEP 1, the most common side effects were gastrointestinal — nausea and diarrhea topped the list. The trial described them as typically transient, usually mild to moderate, and most likely to fade as your body adjusts and the dose climbs in small steps. That word transient turned out to carry a lot.

Here's the stat that gets lost in the panic of week two: yes, more people on semaglutide than placebo quit over stomach side effects — but the rate was 4.5% versus 0.8%. So the GI symptoms were common, and the share of people who walked away over them was still small. Most people who felt awful did not, in the end, stop.

That titration schedule — the slow climb from a tiny starting dose up the ladder, the thing r/Ozempic calls "starting dose gang" — exists precisely so your gut gets a vote. I treated mine like a countdown to the "real" dose. Looking back, the slow ramp wasn't a delay to muscle through; it was the design working exactly as intended.

If the nausea hasn't settled after a couple of weeks, that's a phone call to your prescriber, not a reason to white-knuckle it alone. Holding at your current dose, or climbing slower, fixes it for a lot of people. Suffering in silence was never the plan the trial was built around.

What I'd tell my past self: the worst of it clusters up front. Plan your first month assuming you might feel off, then expect it to get easier — because for most people, it does.

How long am I signing up for? Longer than I thought

This is the lesson that rearranged everything I assumed, and it comes from a second trial: STEP 4.

In STEP 4, everyone started on semaglutide. After 20 weeks, half kept going and half were quietly switched to placebo. The group that stayed on it lost another 7.9% of body weight over the weeks that followed. The group that stopped regained 6.9%. The gap between continuing and stopping landed at about 14.8 percentage points — almost all of it because the weight came back the moment the medicine left.

Read that one twice, because it's the whole story in one line. Stopping wasn't neutral. Stopping put the car in reverse.

This is managing a chronic condition, not finishing a cleanse. The biology that pushes weight back up doesn't get cured in a few months. It gets held in check for exactly as long as you keep holding it.

I'd walked in half-expecting a hard season followed by a finish line. STEP 4 retired that idea without much ceremony. For most people, a GLP-1 behaves more like blood-pressure medication than a round of antibiotics: it works while you take it, and the effect loosens its grip when you don't. That's not a knock on the drug — it's just what the trial says, and knowing it up front changes how you plan, how you budget, and how you talk to your doctor about the years, not the weeks.

None of which means you're chained to it for life. It means stopping is a decision you make with a clinician and a plan — not something you drift into because a refill lapsed and life got busy.

The food noise going quiet is the part no table can capture

Here's the thing the trials never put in a table, and the one people ask me about most.

A lot of us carry a constant low hum — the running negotiation about the next snack, the second helping, the thing calling from the cupboard at 9 p.m. On these drugs, people describe that hum going strangely silent. The clinical phrase is reduced appetite. The lived version, the one r/GLP1 named "food noise," is that the volume drops to zero and the quiet is almost unsettling at first.

It hit me on a random Tuesday. I'd skipped lunch without noticing, and the realization genuinely startled me, because forgetting to eat had never once been my problem.

This is real, and it's reported widely enough that it's worth naming so it doesn't blindside you. Two honest caveats, though:

• It's a tool, not a personality transplant. The quiet hands you room to make different choices. It doesn't make them for you.
• It can fade if you stop, right alongside the appetite — which loops straight back to the long-road lesson above.

What surprised me wasn't the weight. It was learning how much of my head had been quietly occupied by food, for years, without my ever sending in the eviction notice.

Protein and movement, from day one — not day ninety

I started lifting in month three. I should have started in week one.

When weight comes off fast, some of what leaves is muscle, not just fat — that's true of any rapid loss, GLP-1 or not. The scale measures total body weight; it has no idea what kind of weight just walked out the door. By the time I understood that, I'd already shed a chunk of it the wrong way.

You don't need a clever program. You need two boring habits, held steady:

1. Eat the protein first. With a smaller appetite, under-eating protein is shockingly easy to do without noticing. Make it the thing you reach for before anything else on the plate.
2. Keep moving, and add some resistance. Walking is great. Walking plus something that makes your muscles work — bands, bodyweight, dumbbells, whatever you'll genuinely keep doing — is the combination that helps protect lean mass while the fat comes off.

Think of the drug as the thing that quiets the room, and these habits as what you decide to do with the quiet. The medicine handles your appetite. It has never once picked up a dumbbell for me.

Screen your history before the first shot, not after

Before the pen ever comes out of the box, there's a conversation to have — and it isn't the optional kind.

Semaglutide for weight management carries a boxed warning for thyroid C-cell tumors. It's contraindicated — a flat no — for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or a condition called Multiple Endocrine Neoplasia type 2 (MEN 2). That isn't a "weigh the pros and cons" item. It's a stop sign, and it's the first thing a careful prescriber asks about.

A few other safety signals are worth carrying in with you:

• Pancreas. Acute pancreatitis has been reported in people on GLP-1 medicines, semaglutide included. If it's suspected, the drug gets stopped. Severe, stubborn stomach pain is not "just the side effects" — it's a call-your-doctor symptom, same day.
• Gallbladder. Rapid weight loss raises gallstone risk across the board, and the label reflects it: in the adult weight-management trials, gallstones turned up in 1.6% of people on the drug versus 0.7% on placebo. Small numbers, but worth knowing the warning signs.
• Everything else on your shelf. Your full medication list, your medical history, whether you're pregnant or planning to be — all of it belongs on the table before the first dose, not discovered after.

The single most useful thing I did before starting wasn't research. It was an honest, unhurried sit-down with a clinician who actually read my history out loud. The injection is the easy part. The screening is the part that keeps you safe.

I'll be blunt about this one, because it's the lesson that scares people into skipping it, and skipping it is the exact wrong move. The contraindications exist because the risks are specific and real for specific people. Most readers won't have them. The only way to learn which group you're in is to ask.

The cost and the paperwork will blindside you if you let them

The medicine wasn't what tripped me up. The bureaucracy was.

In the US, the list price for the obesity version runs well over $1,000 a month before insurance or assistance — and what you end up paying swings wildly with your coverage. Some plans cover it cleanly. Many require a prior authorization, the documentation ritual where your prescriber has to justify the prescription to your insurer before a single pen ships. Denials happen. Appeals happen. "PA denied again" is practically its own genre on the GLP-1 forums for a reason. It's tedious, and it's worth bracing for.

A handful of logistics I never saw coming:

• The shot is weekly, and it becomes a habit. Same day, same rhythm. It turns into muscle memory faster than you'd expect, even if the first few feel like a whole production.
• Storage and travel take a little planning. The pens have temperature rules. A weekend away is fine; you just can't be careless about the cooler bag.
• Supply can wobble. GLP-1 demand has triggered shortages before. Don't let your stock run to zero before you've sorted out the refill.

I'm not going to hand you a pharmacy hack or a code, because that isn't what this is — and honestly, the pricing landscape shifts too fast for any shortcut to age well. What's worth doing is asking your plan about formulary status and coverage paths up front, so the cost reality arrives as information you planned for instead of a surprise three weeks in.

The medicine was the simple part. The system wrapped around it was the part I had to learn to navigate.

What I'd say across the table, the night before

If I could lean across that kitchen table to the person stalling over the pen, I'd keep it to four things — one for each question.

The drug is strong, and STEP 1 backs that up, but 14.9% is an average and where you land on the curve is partly out of your hands, so don't pin your self-worth to a number from a stranger's trial. The first month may feel rough; it usually eases, and that slow dose climb is doing its job. This is no sprint — STEP 4 made that plain the moment the weight returned when the medicine stopped, so plan for a long relationship, not a quick win. And before any of it, sit down with a clinician who'll actually screen your history, because the contraindications are specific and the safety conversation comes first.

Protein and movement from day one. Patience with the scale. Eyes open on the cost.

The honest summary is unglamorous: this is a real tool with real evidence behind it, and a serious medication with real boundaries, both at once. Holding both of those in your head at the same time is what lets you start this well.

None of this is a prescription, and none of it replaces the conversation that matters most. Everything here comes from published clinical trials and the approved label — the deciding part happens between you and a doctor who knows your history in a way no article ever can. If a GLP-1 sounds like it might fit your life, that's the thing to bring to your next visit. Start there. The pen can wait three more days.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app